PURPOSE: Lymphopenia as a likely index of poor systemic immunity is an independent predictor of inferior outcome in patients with clear cell renal cell carcinoma (RCC). We sought to evaluate the prognostic relevance of preoperative absolute lymphocyte count (ALC) in a cohort of patients with papillary RCC (PRCC). MATERIALS AND METHODS: A prospectively maintained, renal cancer database was analyzed. Patients with preoperative ALC, within 3 months before surgery, were eligible for the study. Those with multifocal or bilateral renal tumors were excluded. Correlations between ALC and age, gender, smoking, Charlson comorbidity index, pathologic T category, PRCC subtype, and TNM stage were evaluated. Differences in overall survival (OS) and cancer-specific survival by ALC status were assessed using the log-rank test and cumulative incident estimators, respectively. Cox proportional hazards model was used for multivariable analyses. RESULTS: A total of 192 patients met the inclusion criteria. As a continuous variable, preoperative ALC was associated with higher TNM stage (P = 0.001) and older age (P = 0.01). As a dichotomous variable, lymphopenia (<1,300 cells/µl) was associated with higher TNM stage (P = 0.003). On multivariable analyses, controlling for covariates, after a median follow-up of 37.3 months, lymphopenia was associated with inferior OS (hazard ratio = 2.3 [95% CI: 1.2-4.3], P = 0.011) and trended to significance for cancer-specific survival (P = 0.071). Among patients with nonmetastatic disease and lymphopenia, OS at 37.5 months was shorter compared with those with normal ALC (83% vs. 93%, P = 0.0006). CONCLUSIONS: In patients with PRCC, lymphopenia is associated with lower survival independent of TNM stage, age, and histology. ALC may provide an additional preoperative prognostic factor.
PURPOSE:Lymphopenia as a likely index of poor systemic immunity is an independent predictor of inferior outcome in patients with clear cell renal cell carcinoma (RCC). We sought to evaluate the prognostic relevance of preoperative absolute lymphocyte count (ALC) in a cohort of patients with papillary RCC (PRCC). MATERIALS AND METHODS: A prospectively maintained, renal cancer database was analyzed. Patients with preoperative ALC, within 3 months before surgery, were eligible for the study. Those with multifocal or bilateral renal tumors were excluded. Correlations between ALC and age, gender, smoking, Charlson comorbidity index, pathologic T category, PRCC subtype, and TNM stage were evaluated. Differences in overall survival (OS) and cancer-specific survival by ALC status were assessed using the log-rank test and cumulative incident estimators, respectively. Cox proportional hazards model was used for multivariable analyses. RESULTS: A total of 192 patients met the inclusion criteria. As a continuous variable, preoperative ALC was associated with higher TNM stage (P = 0.001) and older age (P = 0.01). As a dichotomous variable, lymphopenia (<1,300 cells/µl) was associated with higher TNM stage (P = 0.003). On multivariable analyses, controlling for covariates, after a median follow-up of 37.3 months, lymphopenia was associated with inferior OS (hazard ratio = 2.3 [95% CI: 1.2-4.3], P = 0.011) and trended to significance for cancer-specific survival (P = 0.071). Among patients with nonmetastatic disease and lymphopenia, OS at 37.5 months was shorter compared with those with normal ALC (83% vs. 93%, P = 0.0006). CONCLUSIONS: In patients with PRCC, lymphopenia is associated with lower survival independent of TNM stage, age, and histology. ALC may provide an additional preoperative prognostic factor.
Authors: Luca Cindolo; Paolo Chiodini; Sabine Brookman-May; Ottavio De Cobelli; Matthias May; Stefano Squillacciotti; Cosimo De Nunzio; Andrea Tubaro; Ioan Coman; Bodgan Feciche; Michael Truss; Manfred P Wirth; Orietta Dalpiaz; Thomas F Chromecki; Shahrock F Shariat; Manuel Sanchez-Chapado; Maria del Carmen Santiago Martin; Bernardo Rocco; Luigi Salzano; Giuseppe Lotrecchiano; Francesco Berardinelli; Luigi Schips Journal: BJU Int Date: 2013-03-07 Impact factor: 5.588
Authors: M Santoni; U De Giorgi; R Iacovelli; A Conti; L Burattini; L Rossi; S Luca Burgio; R Berardi; G Muzzonigro; E Cortesi; D Amadori; S Cascinu Journal: Br J Cancer Date: 2013-09-05 Impact factor: 7.640
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640
Authors: M Scartozzi; M Bianconi; L Faloppi; C Loretelli; A Bittoni; M Del Prete; R Giampieri; E Maccaroni; S Nicoletti; L Burattini; D Minardi; G Muzzonigro; R Montironi; S Cascinu Journal: Br J Cancer Date: 2012-11-29 Impact factor: 7.640
Authors: Martin Grimm; Johan Rieth; Sebastian Hoefert; Michael Krimmel; Sven Rieth; Peter Teriete; Susanne Kluba; Thorsten Biegner; Adelheid Munz; Siegmar Reinert Journal: Eur Arch Otorhinolaryngol Date: 2016-02-29 Impact factor: 2.503
Authors: Reza Mehrazin; Essel Dulaimi; Robert G Uzzo; Karthik Devarjan; Jianming Pei; Marc C Smaldone; Alexander Kutikov; Joseph R Testa; Tahseen Al-Saleem Journal: Ther Adv Urol Date: 2017-10-31